Thrombelastography: Current clinical applications and its potential role in interventional cardiology

Platelets

Volumn 17, Issue 8, 2006, Pages 509-518

  Hobson, A R ^a   Agarwala, R A ^a   Swallow, R A ^a   Dawkins, K D ^a   Curzen, N P ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspirin; Clopidogrel; Clotting; Platelets; Vascular

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; BATROXOBIN; BLOOD CLOTTING FACTOR 13A; CITRIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HEPARIN LYASE; INFUSORIAL EARTH; KAOLIN; THROMBOPLASTIN; TRANEXAMIC ACID;

ANALYZER; CORONARY ARTERY DISEASE; CORONARY STENT; HEMOSTASIS; HUMAN; IN-STENT RESTENOSIS; INTERMETHOD COMPARISON; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LABORATORY TEST; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY; THROMBOSIS;

ANTICOAGULANTS; DRUG MONITORING; HUMANS; POSTOPERATIVE HEMORRHAGE; THROMBELASTOGRAPHY; THROMBOSIS;

EID: 33751546229     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100600935259     Document Type: Review

References (63)

1. Kettner SC, Panzer OP, Kozek SA, Seibt FA, Stoiser B, Kofler J, Locker GJ, Zimpfer M. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery. Anesth Analg 1999;89:580-584.
2. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thrombelastography in the assessment of platelet function. Clin Appl Thromb Hemost 2003;9:137-142.
3. Hartert H. Thrombelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951;117:189-203.
4. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992;69:307-313.
5. Mousa SA, Khurana S, Forsythe MS. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thrombelastography: Differentiation among glycoprotein IIb/IIIa antagonists. Arterioscler Thromb Vasc Biol 2000;20:1162-1167.
6. Waters JH, Anthony DG, Gottlieb A, Sprung JU. Bleeding in a patient receiving platelet aggregation inhibitors. Anesth Analg 2001;93:878-882.
7. Artang R, Jensen E, Pedersen F, Frandsen NJ. Thrombelastography in healthy volunteers, patients with stable angina and acute chest pain. Thromb Res 2000;97:499-503.
8. Samama CM. Thrombelastography: The next step. Anesth Analg 2001;92:563-564.
9. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thrombelastography-guided transfusion algorithm reduces transfusion complex cardiac surgery. Anesth Analg 1999;88:312-319.
10. Kaufmann CR, Dwyer KM, Crews JD, Dols SJ, Trask AL. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997;42:716-722.
11. Spiess BD, Tuman KJ, McCarthy RJ, DeLaria GA, Schillo R, Ivankovich AD. Thrombelastography as an indicator of postcardiopulmonary bypass coagulopathies. J Clin Monit 1987;3:25-30.
12. Cammerer U, Dietrich W, Rampf T, Braun S, Richter J. The predictive vale of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-57.
13. Roysten D. Aprotinin prevents bleeding and has effects on platelets and Fibrinolysis. J Cardiothorac Vasc Anesth 1991;5:18-23.
14. Whitten CW, Greilich PE. Thrombelastography: Past, present, and future. Anesthesiology 2000;92:1223-1225.
15. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985;64:888-896.
16. McCarthy RJ, Tuman KJ, Chen B, Ivankovich AD. Platelet integrin inhibition with c7E3 enhances the correlation between platelet aggregrometry and thrombelastographic (TEG®) MA values. Anesth Analg 1998;86:S219.
17. Luddington RJ. Thrombelastography/thrombelastometry. Clin Lab Haem 2005;27:81-90.
18. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci 1981;26:388-393.
19. Kelley DA, Tuddenham EG. Haemostatic problems in liver disease. Gut 1986;27:339-349.
20. Orlikowski CE, Payne AJ, Moodley J, Rocke DA. Thrombelastograph after aspirin ingestion in pregnant and non-pregnant subjects. Br J Anaesth 1992;69:159-161.
21. Dorman BH, Spinale FG, Bailey MK, Kratz JM, Roy RC. Identification of patients at risk of excessive blood loss during coronary artery bypass surgery: Thrombelastograph versus coagulation screen. Anesth Analg 1993;76:694-700.
22. Gelb AB, Roth RI, Levin J, London MJ. Changes in blood coagulation during and following cardiopulmonary bypass. Am J Clin Pathol 1996;106:87-99.
23. Kettner SC, Kozek SA, Groetzner JP, Gonano C, Schellongowski A, Kucera M, Zimpfer M. Effects of hypothermia on thrombelastography in patients undergoing cardiopulmonary bypass. Br J Anaesth 1998;80:313-317.
24. McGrath DJ, Ceboni E, Frumento RJ, Hirsh AL, Bennett GE. Thrombelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005;100:1576-1583.
25. Gurbel PA, Bliden KP, Gruger K, Cho PW, Zaman KA, Kreutz PR, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: Results of the Prepare Post-stenting Study. J Am Coll Cardiol 2005;46:1820-1826.
26. Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783-787.
27. Tuman KJ, McCarthy RJ, Patel RV, Ivankovich AD. Comparison of thrombelastography and platelet aggregometry. Anesthesiology 1991;75:A433.
28. Anderson K, Hurlen M, Arnesen H, Selejeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42.
29. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schnizel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005;51:957-965.
30. Gorog DA, Douglas H, Ahmed N, Lefroy DC, Davies GJ. Coronary angioplasty enhances platelet reactivity through von Willebrand factor release. Heart 2003;89:329-330.
31. Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, Delao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous intervention: The role of dual drug resistance. J Am Coll Cardiol 2006;47:27-33.
32. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous intervention despite clopidogrel pre-treatment. J Am Coll Cardiol 2004;43:1122-1126.
33. Bailey LA, Sistino JJ, Uber WE. Is platelet function as measured by Thrombelastography monitoring in whole blood affected by platelet inhibitors?. J Extra Corpor Technol 2005;37:43-47.
34. Tanaka KA, Sziam F, Kelly AB, Vega JD, Levy JH. Clopidogrel and cardiac surgical patients: Implications for platelet function monitoring and postoperative bleeding. Platelets 2004;15:325-332.
35. Swallow RA, Agarwala RA, Dawkins KD, Curzen NP. Thrombelastography: A novel bedside tool to assess the effects of antiplatelet therapy? Platelets 2006;17:385-92.
36. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC. A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical aggregation. J Lab Clin Med 2004;143:301-309.
37. Mobley JE, Bresee SJ, Wortham DC, Craft RM, Snider CC, Carroll RC. Frequency of nonresponse antiplatelet activity of clopidogrel during pre-treatment for cardiac catheterisation. Am J Cardiol 2004;93:456-458.
38. Tantry US, Bliden KP, Gurbel PA. Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachadonic acid stimulation. J Am Coll Cardiol 2005;46:1705-1709.
39. Ault K, Cannon C, Mitchell J, McCahan J, Tracy RP, Novotny WF, Reimann JD, Braunwald E. Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial. J Am Coll Cardiol 1999;33:634-639.
40. Mehta S, Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41(4 Supp S):S9-S88.
41. Greilich PE, Alving BM, Longnecker D, et al. Near site monitoring of the antiplatelet drug abciximab using the Hemodyne Analyser and Modified Thromboelastograph. J Cardiothorac Vasc Anesth 1999;13:58-64.
42. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
43. Kubler W, Darius H. Primary prevention of coronary heart disease with aspirin. Z Kardiol 2005;94:66-73.
44. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994;330:1287-1294.
45. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235.
46. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002;108:115-119.
47. Andersen K, Hurlen M, Arnesen H, Seljeflot I. Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2003;108:37-42.
48. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Card 2005;95:973-975.
49. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. Am Coll Cardiol 2003;41:961-965.
50. Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49.
51. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
52. CURE Steering Committee. Effects of clopidogrel in addition in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
53. The CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
54. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252:233-238.
55. Colwell JA, Nair RM, Halushka PV, Rogers C, Whetsell A, Sagel J. Platelet adhesion and aggregation in diabetes mellitus. Metabolism 1979;28(4 Suppl 1):394-400.
56. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Jarvinen H. Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in non-diabetic subjects. Int J Obes Relat Metab Disord 2003;27:907-911.
57. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-3175.
58. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
59. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic GA, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
60. Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45:2088-2092.
61. Wenaweser P, Dorffler MJ, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;45:1748-1752.
62. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results of the CREST Study. J Am Coll Cardiol 2005;46:1827-1832.
63. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908-2913.